Cargando…

Detection of myeloma cell-derived microvesicles: a tool to monitor multiple myeloma load

The persistence of tumor load in multiple myeloma (MM) lead to relapse in patients achieving complete remission (CR). Appropriate and effective methods of myeloma tumor load monitoring are important for guiding clinical management. This study aimed to clarify the value of microvesicles in monitoring...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhao-Yun, Meng, Nan-Hao, Cao, Pan-Pan, Peng, Feng-Ping, Luo, Jing-Yi, Wang, Hao, Jiang, Feng-Juan, Lu, Jin, Fu, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987071/ https://www.ncbi.nlm.nih.gov/pubmed/36879302 http://dx.doi.org/10.1186/s40164-023-00392-4

Ejemplares similares

Sensitive multiple myeloma disease monitoring by mass spectrometry
por: Santockyte, Rasa, et al.
Publicado: (2021)

IgA Type Multiple Myeloma, Clinical Features, and Prognosis
por: Wang, Ling, et al.
Publicado: (2018)

Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma
por: Gao, Tiantao, et al.
Publicado: (2022)

Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
por: Chakraborty, Rajshekhar, et al.
Publicado: (2021)

Smoldering Multiple Myeloma Arising in Ulcerative Colitis
por: Yang, Xue, et al.
Publicado: (2018)

Bone marrow‐derived mesenchymal stem cells inhibit NK cell function via Tim‐3/galectin‐9 in multiple myeloma patients
por: Liu, Zhao‐Yun, et al.
Publicado: (2023)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Impact of mitochondrial DNA mutations in multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2020)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

A systematic classification of death causes in multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2018)

Characterization of rare germline variants in familial multiple myeloma
por: Catalano, Calogerina, et al.
Publicado: (2021)

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
por: Tariq, Syed Maaz, et al.
Publicado: (2023)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
por: Ren, Quan, et al.
Publicado: (2023)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
por: Caers, Jo, et al.
Publicado: (2018)

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
por: Noori, Somayya, et al.
Publicado: (2023)

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma
por: Jain, Tania, et al.
Publicado: (2017)

Multiple myeloma: family history and mortality in second primary cancers
por: Chattopadhyay, Subhayan, et al.
Publicado: (2018)

Racial differences as predictors of outcomes in young patients with multiple myeloma
por: Bao, Alicia, et al.
Publicado: (2022)

Infectious complications of bispecific antibody therapy in patients with multiple myeloma
por: Sim, Beatrice Z., et al.
Publicado: (2023)

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma
por: Leng, Siyang, et al.
Publicado: (2020)

Multiple myeloma cell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation
por: Arendt, Bonnie K., et al.
Publicado: (2014)

A report on the syndrome of inappropriate anti-diuretic hormone secretion associated with multiple myeloma
por: Tang, Ran, et al.
Publicado: (2020)

A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2021)

Efficacy and safety of tandem autologous stem cell transplantation in multiple myeloma: a retrospective single-center analysis
por: Wu, Shunquan, et al.
Publicado: (2023)

Orbital and Choroidal Plasmacytoma in Recurrent Multiple Myeloma: A Case Report
por: Choi, Ji Ho, et al.
Publicado: (2021)

Utility of flow cytometry screening before MRD testing in multiple myeloma
por: Panakkal, Vandana, et al.
Publicado: (2023)

Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma
por: Evers, Marietheres, et al.
Publicado: (2023)

Potential value of pre-planned imaging of bone disease in multiple myeloma
por: Gundesen, Michael T., et al.
Publicado: (2023)

Identification of novel genetic loci for risk of multiple myeloma by functional annotation
por: Macauda, Angelica, et al.
Publicado: (2023)

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2019)

A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma
por: Spencer, Andrew, et al.
Publicado: (2019)

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma
por: Atrash, Shebli, et al.
Publicado: (2018)

Dissecting racial disparities in multiple myeloma—clues from differential immunoglobulin levels
por: Bunce, C. M., et al.
Publicado: (2020)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma
por: Hulin, Cyrille, et al.
Publicado: (2021)

Real-world renal function among patients with multiple myeloma in the United States
por: Mikhael, Joseph, et al.
Publicado: (2021)

SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma
por: Sgherza, Nicola, et al.
Publicado: (2021)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_92fqcb0knig3huj4nracntki6k